Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
- PMID: 11118462
- DOI: 10.1200/JCO.2000.18.24.4016
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
Abstract
Purpose: To provide an estimate of long-term prognosis for patients with osteosarcoma of the extremity treated in a single institution with neoadjuvant chemotherapy and observed for at least 10 years.
Patients and methods: Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM). Postoperatively, good responders (90% or more tumor necrosis) received the same three drugs used before surgery, whereas poor responders (less than 90% tumor necrosis) received ifosfamide and etoposide in addition to those three drugs.
Results: For the 164 patients who entered the study between September 1986 and December 1989, surgery was a limb salvage in 136 cases (82%) and a good histologic response was observed in 117 patients (71%). At a follow-up ranging from 10 to 13 years (median, 11.5 years), 101 patients (61%) remained continuously free of disease, 61 relapsed, and two died of ADM-induced cardiotoxicity. There were no differences in prognosis between good and poor responding patients. ADM-induced cardiotoxicity (six patients), male infertility (10 of the 12 assessable patients), and second malignancies (seven patients) were the major complications of chemotherapy. Despite the large number of limb salvages performed, only four local recurrences (2.4%) were registered.
Conclusion: With an aggressive neoadjuvant chemotherapy, it is possible to cure more than 60% of patients with nonmetastatic osteosarcoma of the extremity and amputation may be avoided in more than 80% of them. Because local or systemic relapses, myocardiopathies, and second malignancies are possible even 5 years or more after the beginning of treatment, a long-term follow-up is recommended for these patients.
Similar articles
-
Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.Cancer. 1993 Dec 1;72(11):3227-38. doi: 10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c. Cancer. 1993. PMID: 8242546
-
Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience.Oncol Rep. 2000 Sep-Oct;7(5):1129-33. doi: 10.3892/or.7.5.1129. Oncol Rep. 2000. PMID: 10948351
-
Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities.Clin Orthop Relat Res. 1991 Sep;(270):87-98. Clin Orthop Relat Res. 1991. PMID: 1884564
-
An update of Scandinavian studies of osteosarcoma.Cancer Treat Res. 1993;62:293-8. doi: 10.1007/978-1-4615-3518-8_35. Cancer Treat Res. 1993. PMID: 8096745 Review. No abstract available.
-
Adjuvant and neoadjuvant chemotherapy in osteosarcoma.Chir Organi Mov. 2001 Oct-Dec;86(4):253-68. Chir Organi Mov. 2001. PMID: 12056242 Review. English, Italian.
Cited by
-
Revision surgery for periprosthetic fracture of distal femur after endoprosthetic replacement of knee joint following resection of osteosarcoma.Front Oncol. 2024 Feb 12;14:1328703. doi: 10.3389/fonc.2024.1328703. eCollection 2024. Front Oncol. 2024. PMID: 38410108 Free PMC article.
-
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.Oncoimmunology. 2018 Aug 6;7(11):e1465161. doi: 10.1080/2162402X.2018.1465161. eCollection 2018. Oncoimmunology. 2018. PMID: 30393581 Free PMC article.
-
Detection of somatostatin receptors in human osteosarcoma.World J Surg Oncol. 2008 Sep 10;6:99. doi: 10.1186/1477-7819-6-99. World J Surg Oncol. 2008. PMID: 18783595 Free PMC article.
-
MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression.Mol Ther. 2011 Jun;19(6):1123-30. doi: 10.1038/mt.2011.53. Epub 2011 Mar 22. Mol Ther. 2011. PMID: 21427707 Free PMC article.
-
Long-term functional outcome and quality of life following rotationplasty for treatment of malignant tumors.BMC Musculoskelet Disord. 2015 Sep 24;16:262. doi: 10.1186/s12891-015-0721-0. BMC Musculoskelet Disord. 2015. PMID: 26403306 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical